Some of the nation’s leading genitourinary cancer physicians will speak about the latest advances in care at an OncLive State of the Science Summit held in collaboration with Vanderbilt-Ingram Cancer Center.

A five-year follow-up study of U.S. men who received prostate cancer treatment is creating a road map for future patients to clarify expectations and enable men to make informed choices about care.

An analysis of more than 140,000 people of European ancestry has identified blood protein biomarkers associated with prostate cancer risk.

Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.

Vanderbilt University Medical Center is the world’s first site to treat a patient in the TULSA-PRO Ablation Clinical Trial (TACT), which employs an emerging therapy that uses MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation. Investigators, David Penson, M.D.

The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment. “Nationwide we’re seeing great promise with this approach […]